Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota.
J Arthroplasty. 2018 Dec;33(12):3746-3753. doi: 10.1016/j.arth.2018.08.016. Epub 2018 Aug 27.
Two-stage revision utilizing spacers loaded with high-dose antibiotic cement prior to reimplantation remains the gold standard for treatment of periprosthetic joint infections (PJI) in total hip arthroplasty (THA) in North America, but there is a paucity of data on mid-term outcomes. We sought to analyze the survivorship free of infection, clinical outcomes, and complications of a specific articulating spacer utilized during 2-stage revision.
One hundred thirty-five hips (131 patients) undergoing a 2-stage revision THA for PJI with a specific articulating antibiotic spacer design from 2005 to 2013 were retrospectively reviewed. Infections were classified according to the Musculoskeletal Infection Society criteria. Mean age at resection was 65 years and mean follow-up was 5 years (rang, 2-10).
Survivorship free of any infection after reimplantation was 92% and 88% at 2 and 5 years, respectively. Patients with a host-extremity grade of C3 compared to all patients with a host grade of A [hazard ratio (HR) 4.1, P = .05] were significant risk factors for poorer infection-free survivorship after reimplantation. Harris hip scores improved from a mean of 58 to a mean of 71 in the spacer phase (P = .002) and a mean of 81 post-reimplantation (P = .001). Fourteen (10%) patients dislocated after reimplantation, 9 (7%) of which required re-revision. Trochanteric deficiency (HR 19, P < .0001), dislocation of the articulating spacer prior to reimplantation [which occurred in 7 (5%) patients, 5 of whom subsequently dislocated the definitive implant] (HR 16, P < .0001), and female gender (HR 5, P = .002) were significant risk factors for post-reimplantation dislocation.
Insertion of an articulating antibiotic spacer during a 2-stage revision THA for PJI demonstrates reliable infection eradication and improvement in clinical function, including the spacer phase. Patients with trochanteric deficiency and an articulating spacer dislocation are at high risk of post-reimplantation dislocation; judicial use of a dual-mobility or constrained device should be considered in these patients.
在北美,对于全髋关节置换术(THA)的假体周围关节感染(PJI),两阶段翻修利用载有高剂量抗生素骨水泥的间隔物在再植入前进行仍然是金标准,但中期结果数据有限。我们旨在分析一种特定的关节式抗生素间隔物在两阶段翻修中使用的无感染生存率、临床结果和并发症。
回顾性分析了 2005 年至 2013 年间,131 名患者(135 髋)接受两阶段翻修 THA 治疗 PJI 的资料,采用特定的关节式抗生素间隔物设计。感染根据肌肉骨骼感染协会的标准进行分类。切除时的平均年龄为 65 岁,平均随访 5 年(范围 2-10 年)。
再植入后无任何感染的生存率分别为 92%和 88%,在 2 年和 5 年时。与所有宿主分级为 A 的患者相比,宿主-肢体分级为 C3 的患者(风险比 [HR] 4.1,P=.05)是再植入后感染无生存率较差的显著危险因素。在间隔期,Harris 髋关节评分从 58 分平均提高到 71 分(P=.002),再植入后平均提高到 81 分(P=.001)。14 例(10%)患者在再植入后脱位,其中 9 例(7%)需要再次修正。转子下缺陷(HR 19,P<.0001)、在再植入前关节式间隔物脱位(发生在 7 例患者中,其中 5 例随后脱位了最终植入物)(HR 16,P<.0001)和女性(HR 5,P=.002)是再植入后脱位的显著危险因素。
在两阶段翻修 THA 治疗 PJI 期间插入关节式抗生素间隔物可可靠地消除感染并改善临床功能,包括间隔期。转子下缺陷和关节式间隔物脱位的患者再植入后脱位的风险较高;应考虑在这些患者中使用双动或约束装置。